<DOC>
	<DOCNO>NCT00371137</DOCNO>
	<brief_summary>The objective trial evaluate safety efficacy Xyrem® compare placebo treatment fibromyalgia randomize , double blind , placebo control , parallel group trial .</brief_summary>
	<brief_title>A Safety Efficacy Study Xyrem® Subjects With Fibromyalgia</brief_title>
	<detailed_description>The trial randomize , double blind , placebo control , parallel group trial subject diagnose fibromyalgia accordance American College Rheumatology . Total duration twenty-one ( 21 ) week trial participation . Subjects undergo screen withdrawal/washout period last five ( 5 ) week combine , follow baseline period last one ( 1 ) week . Total treatment duration fourteen ( 14 ) week follow one ( 1 ) week safety follow-up post treatment period . During screen withdrawal/washout period , study medication give ; however rescue medication acetaminophen ( 4 gram per day ) allow .</detailed_description>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Sodium Oxybate</mesh_term>
	<criteria>Male female subject , 18 year old meet American College Rheumatology ( ACR ) diagnostic criterion fibromyalgia . Subjects exclude history rheumatic disease disorder may compromise reliable representation subjective symptom . Any condition cause risk subject participate trial also reason exclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>FMS</keyword>
	<keyword>Fibro</keyword>
	<keyword>pain</keyword>
	<keyword>Body pain</keyword>
	<keyword>tenderness</keyword>
	<keyword>joint pain</keyword>
	<keyword>stiffness</keyword>
	<keyword>muscular pain</keyword>
</DOC>